A Cost-Effectiveness Analysis Of An Adenocarcinoma Risk Prediction Multi-Biomarker Assay For Patients With Barrett’s Esophagus

References

• Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett’s esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010;23(6):451–457. doi:10.1111/j.1442-2050.2010.01054.x20353441
   PubMedGoogle Scholar
• Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2015;111(1):30–50. doi:10.1038/ajg.2015.32226526079
   PubMedGoogle Scholar
• Goldblum JR. Controversies in the diagnosis of Barrett esophagus and Barrett-related dysplasia: one pathologist’s perspective. Arch Pathol Lab Med. 2010;134(10):1479–1484. doi:10.1043/2010-0249-RA.120923304
   PubMedGoogle Scholar
• Visrodia K, Singh S, Krishnamoorthi R, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology. 2016;150(3):599–607 e597. doi:10.1053/j.gastro.2015.11.04026619962
   PubMedGoogle Scholar
• Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–1383. doi:10.1056/NEJMoa110304221995385
   PubMed Web of Science ®Google Scholar
• Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9(3):220–227. quiz e226. doi:10.1016/j.cgh.2010.11.00821115133
   PubMedGoogle Scholar
• Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141(4):1179–1186, 1186 e1171. doi:10.1053/j.gastro.2011.06.05521723218
   PubMedGoogle Scholar
• Sinh P, Anaparthy R, Young PE, et al. Clinical outcomes in patients with a diagnosis of “indefinite for dysplasia” in Barrett’s esophagus: a multicenter cohort study. Endoscopy. 2015;47(8):669–674. doi:10.1055/s-0034-139196625910065
   PubMedGoogle Scholar
• Duits LC, Phoa KN, Curvers WL, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64(5):700–706. doi:10.1136/gutjnl-2014-30727825034523
   PubMed Web of Science ®Google Scholar
• Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–146. doi:10.1093/jnci/dji02415657344
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2017. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf Accessed 10 9, 2019.
   Google Scholar
• Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138(3):176–186. doi:10.7326/0003-4819-138-3-200302040-0000912558356
   PubMed Web of Science ®Google Scholar
• Inadomi JM. Surveillance in Barrett’s esophagus: a failed premise. Keio J Med. 2009;58(1):12–18.19398879
   PubMedGoogle Scholar
• Gordon LG, Mayne GC, Hirst NG, Bright T, Whiteman DC, Watson DI. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett’s esophagus. Gastrointest Endosc. 2014;79(2):242–256 e246. doi:10.1016/j.gie.2013.07.04624079411
   PubMedGoogle Scholar
• Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460–468. doi:10.1053/j.gastro.2011.04.06121679712
   PubMed Web of Science ®Google Scholar
• Bulsiewicz WJ, Kim HP, Dellon ES, et al. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11(6):636–642. doi:10.1016/j.cgh.2012.10.02823103824
   PubMed Web of Science ®Google Scholar
• Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–1217. doi:10.1001/jama.2014.251124668102
   PubMed Web of Science ®Google Scholar
• Critchley-Thorne RJ, Duits LC, Prichard JW, et al. A tissue systems pathology assay for high-risk Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2016;25(6):958–968. doi:10.1158/1055-9965.EPI-15-116427197290
   PubMedGoogle Scholar
• Critchley-Thorne RJ, Davison JM, Prichard JW, et al. A tissue systems pathology test detects abnormalities associated with prevalent high-grade dysplasia and esophageal cancer in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2017;26(2):240–248. doi:10.1158/1055-9965.EPI-16-064027729357
   PubMedGoogle Scholar
• Prichard JW, Davison JM, Campbell BB, et al. TissueCypher: a systems biology approach to anatomic pathology. J Pathol Inform. 2015;6:48. doi:10.4103/2153-3539.16398726430536
   PubMedGoogle Scholar
• Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140(3):1084–1091. doi:10.1053/j.gastro.2011.01.03021376940
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136(7):2101–2114 e2101–e2106. doi:10.1053/j.gastro.2009.02.062
   PubMed Web of Science ®Google Scholar
• Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143(3):567–575. doi:10.1053/j.gastro.2012.05.01022626608
   PubMed Web of Science ®Google Scholar
• Arias E. United States life tables 2008. NVSS. 2012;61.
   Google Scholar
• Small AJ, Araujo JL, Leggett CL, et al. Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett’s esophagus and confirmed low-grade dysplasia. Gastroenterology. 2015;149(3):567–576 e563; quiz e513–e564. doi:10.1053/j.gastro.2015.04.013
   PubMed Web of Science ®Google Scholar
• Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970–976. doi:10.1136/gutjnl-2011-30073021997553
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119(2):333–338.10930368
   PubMed Web of Science ®Google Scholar
• Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009;7(7):736–742. quiz 710. doi:10.1016/j.cgh.2008.12.02719268726
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Vakil N, Inadomi JM. The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2005;22(2):135–146. doi:10.1111/j.1365-2036.2005.02536.x16011672
   PubMedGoogle Scholar
• Saxena N, Inadomi JM. Effectiveness and cost-effectiveness of endoscopic screening and surveillance. Gastrointest Endosc Clin N Am. 2017;27(3):397–421. doi:10.1016/j.giec.2017.02.005.28577764
   PubMedGoogle Scholar
• Rubenstein JH. Improving the efficiency of Barrett’s esophagus management: do biomarkers hit the mark? Gastrointest Endosc. 2014;79(2):257–259. doi:10.1016/j.gie.2013.09.003.24433630
   PubMedGoogle Scholar
• Das A, Callenberg KM, Styn MA, Jackson SA. Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett’s esophagus who have elevated genomic instability. Endosc Int Open. 2015;4(5):E549–E559.
   Google Scholar
• National Comprehensive Cancer Network. NCCN guideline for patients–esophageal cancer. Available from: http://www.nccn.org/patients/guidelines/esophageal/files/assets/common/downloads/files/esophageal.pdf Accessed 109, 2015.
   Google Scholar
• Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–2288. doi:10.1056/NEJMoa080814519474425
   PubMed Web of Science ®Google Scholar
• Pouw RE, Wirths K, Eisendrath P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010;8(1):23–29. doi:10.1016/j.cgh.2009.07.00319602454
   PubMed Web of Science ®Google Scholar
• Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12(11):1840–1847 e1841. doi:10.1016/j.cgh.2014.04.03424815329
   PubMedGoogle Scholar
• Curvers WL, Ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–1530. doi:10.1038/ajg.2010.17120461069
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2015. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf Accessed 2, 19, 2016.
   Google Scholar
• Gerson LB, Ullah N, Hastie T, Goldstein MK. Does cancer risk affect health-related quality of life in patients with Barrett’s esophagus? Gastrointest Endosc. 2007;65(1):16–25.17185075
   PubMed Web of Science ®Google Scholar
• de Boer AG, Stalmeier PF, Sprangers MA, et al. Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients’ utilities and treatment preferences. Br J Cancer. 2002;86(6):851–857. doi:10.1038/sj.bjc.660020311953814
   PubMedGoogle Scholar
• Haddix A. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. 2nd ed. New York: Oxford University Press; 2003.
   Google Scholar
• Graham JD. Valuing the future: OMB’s refined position. Univ Chi Law Rev. 2007;7:1.
   Google Scholar